New recommendations of a height-based dosing regimen of tobramycin for cystic fibrosis in adults: a population pharmacokinetic analysis
K Koloskoff, DJG Thirion, E Matouk… - Therapeutic drug …, 2023 - journals.lww.com
Background: Acute pulmonary exacerbations (APEs) in patients with adult cystic fibrosis
(CF) are treated with a beta-lactam and an aminoglycoside for activity against Pseudomonas …
(CF) are treated with a beta-lactam and an aminoglycoside for activity against Pseudomonas …
[HTML][HTML] Optimal Therapeutic Drug Monitoring Strategy for IV Aminoglycosides and IV Vancomycin in People with Cystic Fibrosis: A Systematic Review
J Jiang, N Giunio-Zorkin, V Su… - The Canadian Journal of …, 2023 - ncbi.nlm.nih.gov
Background Given altered pharmacokinetics in people with cystic fibrosis (pwCF), there is
debate regarding optimal strategies for therapeutic drug monitoring (TDM) for …
debate regarding optimal strategies for therapeutic drug monitoring (TDM) for …
A pharmacokinetic analysis of tobramycin in patients less than five years of age with cystic fibrosis: Assessment of target attainment with extended-interval dosing …
KJ Downes, A Grim, L Shanley… - Antimicrobial agents …, 2022 - Am Soc Microbiol
Extended interval dosing of tobramycin is recommended for treatment of pulmonary
exacerbations in adults and older children with cystic fibrosis (CF), but data are limited in …
exacerbations in adults and older children with cystic fibrosis (CF), but data are limited in …
Target attainment of extended-interval dosing of tobramycin in patients less than five years of age with cystic fibrosis: A pharmacokinetic analysis
KJ Downes, A Grim, L Shanley, RC Rubenstein… - medRxiv, 2022 - medrxiv.org
Background Extended interval dosing (EID) of tobramycin is recommended for treatment of
pulmonary exacerbations in adults and older children with cystic fibrosis (CF), but data are …
pulmonary exacerbations in adults and older children with cystic fibrosis (CF), but data are …